Hom J T, Butler L D, Riedl P E, Bendele A M
Department of Immunology, Lilly Research Laboratories, Indianapolis, IN 46285.
Eur J Immunol. 1988 Jun;18(6):881-8. doi: 10.1002/eji.1830180608.
Alterations in the progression of the inflammatory disease in mice with established collagen-induced arthritis (CIA) by in vivo treatments with either anti-T cell antibodies or an immunosuppressive drug, whose main targets of action are T cells, were studied. It was demonstrated that the in vivo administration of either monoclonal anti-L3T4, anti-Ly-2 or the combination of anti-L3T4 and anti-Ly-2 failed to modify the inflammatory disease after the arthritis had been initiated. Nevertheless, the progression of disease was decreased by treatments with rabbit anti-mouse lymphocyte sera (ALS) in mice with established CIA. While there was a substantial reduction in the proliferative responses to the T cell mitogen concanavalin A (Con A) in these ALS-treated mice, proliferation to a B cell mitogen, lipopolysaccharide, was unaffected. Furthermore, treatments with anti-Thy-1.2 monoclonal antibody (mAb) by itself did not alter the progression of the ongoing inflammatory disease, but combined treatments with both anti-Thy-1.2 and anti-L3T4 mAb prevented the further advancement of the arthritic disease. Although mice receiving either anti-Thy-1.2 alone or both anti-Thy-1.2 and anti-L3T4 exhibited complete absence of Thy-1+ cells within their inguinal lymph nodes, the proliferative responses to Con A by LN cells from mice treated with the combination of anti-Thy-1.2 and anti-L3T4 were drastically reduced compared to the responses of either the anti-Thy-1.2 or anti-L3T4-treated groups. Finally, daily treatments with cyclosporin A, an immunosuppressive drug which preferentially acts on T cells, were also effective in modifying the clinical course of the arthritic disease in mice with established CIA. These results suggest that immunocompetent cells which express the Thy-1 surface marker, most likely Thy-1+ T cells, may play a role in maintaining and perpetuating the inflammatory disease of established CIA.
通过用抗T细胞抗体或免疫抑制药物进行体内治疗,研究了已建立胶原诱导性关节炎(CIA)的小鼠炎症性疾病进展的改变,这些药物的主要作用靶点是T细胞。结果表明,在关节炎发病后,体内给予单克隆抗L3T4、抗Ly-2或抗L3T4与抗Ly-2的组合均未能改变炎症性疾病。然而,在已建立CIA的小鼠中,用兔抗小鼠淋巴细胞血清(ALS)治疗可降低疾病进展。虽然这些接受ALS治疗的小鼠对T细胞丝裂原刀豆球蛋白A(Con A)的增殖反应大幅降低,但对B细胞丝裂原脂多糖的增殖反应未受影响。此外,单独用抗Thy-1.2单克隆抗体(mAb)治疗并未改变正在进行的炎症性疾病的进展,但抗Thy-1.2和抗L3T4 mAb联合治疗可阻止关节炎疾病的进一步发展。尽管单独接受抗Thy-1.2或同时接受抗Thy-1.2和抗L3T4的小鼠腹股沟淋巴结内完全没有Thy-1+细胞,但与抗Thy-1.2或抗L3T4治疗组相比,接受抗Thy-1.2和抗L3T4联合治疗的小鼠的淋巴结细胞对Con A的增殖反应大幅降低。最后,用环孢素A(一种优先作用于T细胞的免疫抑制药物)进行每日治疗,也能有效改变已建立CIA的小鼠关节炎疾病的临床进程。这些结果表明,表达Thy-1表面标志物的免疫活性细胞,很可能是Thy-1+ T细胞,可能在维持和延续已建立的CIA的炎症性疾病中起作用。